UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop
uniQure NV QURE
News
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
uniQure to Announce Second Quarter 2026 Financial Results
UniQure Shares Soar on Go-to-Market Plan
UniQure to Seek FDA Approval to Market Huntington's Disease Drug
This biotech's stock soared after a 'polarizing' FDA official is stepping down
UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short
UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment
UniQure Shares Drop After More Negative News From FDA on Huntington's Disease Drug
UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment
Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it
United States